糖基因 ST8SIA4在人慢性粒细胞白血病多药耐药中的作用研究

目的：通过研究糖基因 ST8SIA4在人慢性粒细胞白血病（CML ）细胞株 KCL22及其耐阿霉素（ADR）细胞株KCL22／ADR 、CML 患者外周血单个核细胞（PBMC）中表达的差异,明确糖基因 ST8SIA4与人 CML 多药耐药的相关性。方法采用 RT-PCR 和 Western Blot 检测糖基因 ST8SIA4在人 CML 及其耐药细胞株、CML 及 CML 耐药患者 PBMC 中的表达;特异性下调糖基因 ST8SIA4,检测干扰前、后 CML 细胞在体外对化疗药物的敏感性。结果糖基因 ST8SIA4在人 CML 及其耐药细胞株、CML 患者 PBMC 中表达水平比较差异有统计学意义（P＜0．05）;特异性下调 ST8SIA4的表达,增加了 KCL22／ADR 细胞体内、体外的药敏性（P＜0．05）。结论人 CML 细胞株及 CML 患者 PBMC 中糖基因 ST8SIA4的表达差异有统计学意义,这些特征性改变与 CML 多药耐药具有相关性。     

慢性髓系白血病中let-7a-3甲基化态势及其临床意义

目的：探讨慢性髓系白血病（CM L ）患者中let‐7a‐3启动子的甲基化态势及其临床意义。方法建立实时定量甲基化特异性PCR （RQ‐MSP）分别检测25例对照者及52例CML患者骨髓单个核细胞中let‐7a‐3启动子未甲基化水平。结果52例CM L患者未甲基化let‐7a‐3启动子（59．6％）为阳性,而对照组仅1例（4％）阳性,两组比较差异有统计学意义（ P＜0．01）。ROC曲线分析表明,let‐7a‐3启动子未甲基化作为辅助诊断CM L有较好的特异性。未甲基化let‐7a‐3启动子水平与BCR／ABL融合基因转录水平呈显著正相关（ r＝0．641,P＝0．001）,但与患者的白细胞、血小板计数及血红蛋白水平无明显相关性（ P＞0．05）。在慢性期和加速期let‐7a‐3未甲基化水平显著高于急变期。结论 let‐7a‐3基因低甲基化水平随疾病进展而降低。     

慢性肾病患者社会支持和生活质量的相关性研究?

目的：了解慢性肾病(chronic kidney disease,CKD)患者的社会支持和生活质量现状并分析其相关性。方法采用多中心抽样方法,选取2014年3~6月在泸州市3所综合性医院住院的 CKD 患者200例,运用社会支持评定量表(SSRS)和肾病相关生活质量量表(KDQOL-SFTM )进行调查。结果CKD 患者客观支持得分高于全国常模(P <0.05);主观支持、社会支持利用度和社会支持总分得分低于全国常模(P <0.05)。CKD 患者生活质量低于60分项目由低到高为：肾病带来的负担(BKD)、工作状况(WS)、性功能(SexF)、体力所致工作和生活受限(RP)、总体健康(GH)。CKD 患者社会支持和生活质量呈正相关(P <0.05)。结论CKD 患者社会支持低于全国常模,与生活质量呈正相关。加强 CKD 患者的社会支持,改善患者生活质量是目前的主要任务之一。     

eNOS在 EPO调节慢性缺氧心肌细胞线粒体生物合成中的作用机制研究

目的：探讨内皮型一氧化氮合酶（eNOS）在促红细胞生成素（EPO）调节慢性缺氧环境中心肌细胞线粒体生物合成中的作用及其机制。方法采用H9c2心肌细胞,将其于缺氧环境下培养7 d （94％ N2,5％ O2）,建立心肌细胞慢性缺氧模型。将心肌细胞根据不同处理分为缺氧对照组（HC）,20 U／mL重组人 EPO（rhEPO）处理缺氧组（HE）和20 U／mL rhEPO＋ eNOS shRNA干扰处理缺氧组（HR）。以荧光探针检测线粒体数量变化;RT‐PCR检测线粒体DNA相对表达量;Western blot 检测eNOS总蛋白表达及磷酸化水平（p‐eNOS）变化。结果 rhEPO显著增强eNOS磷酸化水平,增加线粒体数量及其DNA相对拷贝数（P＜0．05）;而同时采用shRNA干扰eNOS后,HR组eNOS总蛋白表达及磷酸化水平较HE组降低（P＜0．05）,同时线粒体数量及其DNA相对拷贝数较 HE组减少（P＜0．05）。结论 eNOS的磷酸化激活是EPO增强慢性缺氧心肌细胞线粒体生物合成的重要信号转导机制。     

Shenfu Injection(参附注射液) Suppresses Inflammation by Targeting Haptoglobin and Pentraxin 3 in Rats with Chronic Ischemic Heart Failure

Objective:To investigate the regulatory effects of Shenfu Injection(SFI,参附注射液) on hemodynamic parameters and serum proteins in rats with post-infarction chronic heart failure(CHF).Methods:Forty-five healthy Wistar rats were randomized into three groups:sham,heart failure(model) and SFI group.The CHF was induced by left coronary artery ligation.Seven days after the surgical operation,animals in the sham group and the model group received saline(6.2 mL/kg/d),while animals in the SFI group received SFI(6.2 mL/kg·d) intraperitoneally.Four weeks later,cardiac hemodynamic parameters were measured via the carotid route.The expression of serum proteins was analyzed by two-dimensional electrophoresis and matrixassisted laser desorption/ionization time-of-flight mass spectrometer(MALDI-TOF MS).Results:Recording of hemodynamic parameters showed that left ventricular systolic pressure(LVSP),maximum rate of left ventricular pressure(+dp/dt_(max)) rise,and maximum rate of left ventricular pressure(-dp/dt_(max)) decrease,while the left ventricular end diastolic pressure(LVEDP) rose in the model group compared to those in the sham group(P0.05).The results of the MALDI-TOF MS indicated that haptoglobin(HP),pentraxin 3(PTX3) and alpha-1-antitrypsin were up-regulated,while serum albumin and 40 S ribosomal protein were down-regulated in the model group(P0.05).Compared with the model group,LVSP,+dp/dt_(max)and-dp/dt_(max) were higher,while LVEDP was lower in the SFI group(P0.05).Expression levels of HP and PTX3 were lower than in the model group(P0.05).Conclusion:SFI could improve hemodynamic function and decrease inflammatory reactions in the pathophysiology of CHF.The serum proteins HP and PTX3 could be potential biomarkers for chronic ischemic heart failure,and they could also be the serum protein targets of SFI.     

A Multicenter,Randomized,Double-blind Clinical Study on Wufuxinnaoqing Soft Capsule(五福心脑清胶囊) in Treatment of Chronic Stable Angina Patients with Blood Stasis Syndrome

Objective:To confirm the efficacy and safety of Wufuxinnaoqing Soft Capsule(五福心脑清胶囊,WSC)in the treatment of chronic stable angina(blood stasis syndrome).Methods:A multicenter,randomized,double-blind,placebo-controlled trial with superiority test was designed.A total of 240 patients with chronic stable angina(blood stasis syndrome)from multiple centers were randomly and equally assigned to the treatment group and the control group.Based on standard treatment of Westem medicine,the treatment group was given WSC,while the control group was given WSC mimetic,both for 12 weeks.Observed indicators included the efficacy in angina,the efficacy in Chinese medicine syndrome,the withdrawal or reduce rate of nitroglycerin and routine safety indices.Results:After 12-week treatment,the significant effective rate and total effective rate of the treatment group were significantly better than those of the control group(23.5%vs.9.2%,64.7%vs.30.8%),respectively,with statistically significant difference(P0.01).After 12-week treatment,the decreased points and the decreased rate of angina symptom score in the treatment group were better than in the control group(5.1±4.2 points vs.2.8±3.5 points,44.9%±37.2%vs.25.4%±30.7%)respectively,with significant difference(P0.01).After 12-week treatment,the significant effective rate and total effective rate of the treatment group were better than the control group(respectively,30.3%vs.15.0%,67.2%vs.45.0%,P0.01).After 8-or 12-week treatment,the decreased points and the decreased rate of Chinese medicine syndrome score in the treatment group were better than the control group(P0.05 or P0.01).After 12-week treatment,nitroglycerin withdrawal rate and the withdrawal or reduce rate in treatment group were better than the control group(P0.01).On safety evaluation,the incidence of adverse events(7.563%vs.7.500%)and the incidence of cardiovascular events(0.840%vs.0.000%)in the treatment group were similar with the control group,and the difference was not statistically significant(P0.05).Conclusion:In treatment of chronic stable angina(blood stasis syndrome),WSC can reduce angina attacks and consumption of nitroglycerin,decrease angina severity degree,effectively relieve the blood stasis syndromes,such as chest pain,chest tightness,palpitations,dark purple tongue and other symptoms.Besides,adverse events and cardiovascular adverse events in the treatment group and the control group showed no difference.All shows that the drug is safe and effective.[This study was registered in Chinese Clinical Trial Registry(ChiCTR),with registration number:ChiCTR-TRC-14005158.]     

降钙素原指导慢性阻塞性肺疾病急性加重抗生素治疗的研究进展

急性加重是慢性阻塞性肺疾病(COPD)进展过程中的自然现象,而且在全球范围内的发病率和病死率居高不下。生物标志物(如降钙素原)的检测已经成为诊断及指导COPD抗生素治疗的一种重要工具。然而,关于降钙素原指导COPD治疗的潜在作用仍在临床研究阶段。该文将通过目前国内外现有的证据证明降钙素原可以用于指导COPD的抗生素治疗。